As of Aug 27 2014 12:22PM
Minimum 20 minute delay
  • 8/26/2014 8:02:48 AM

    Announcement under Irish Takeover Rules Relevant Securities in Issue – August 26, 2014

    DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 26, 2014-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on August 25, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 451,825,023 ordinary shares, par value …
  • 8/22/2014 7:00:13 AM

    Covidien Acquires Reverse Medical Corporation

    Generates Opportunity to Leverage Existing Vascular Technologies and Customer Relationships to Drive Increased Market Penetration DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 22, 2014-- Covidien plc (NYSE:COV) today announced it has acquired …
  • 8/21/2014 7:00:14 AM

    FDA Approves Changes to Manufacturing Process for Covidien’s Pipeline™ Embolization Device

    DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 21, 2014-- Covidien plc (NYSE: COV) today announced that the U.S. Food and Drug Administration (FDA) has approved changes to the manufacturing process for the polytetrafluoroethylene (PTFE) coating on the delivery wire of the company’s Pipeline™ embolization device. …

A Partner in Health

Collaborating with physicians and other healthcare professionals, focusing on research and development and maintaining clinical leadership add up to innovative medical solutions that make a difference.

Conscientious Collaboration

Ensuring ethical interactions with healthcare professionals is vital to the global healthcare environment. Covidien’s Conscientious Collaboration platform is our commitment to open communications about the need to ensure compliant interactions with our customers and partners.

One Covidien

One look. One Covidien. Experience the new unified look of Covidien. Easy-to-use labeling. New outside packaging with the same quality products inside. First-class service and support.

Visit Us